DTx Pharma develops RNA-based therapeutics using its FALCON platform, which conjugates short interfering RNAs with fatty acids to enhance cellular uptake and biodistribution beyond the liver. The company targets rare peripheral nervous system, muscle, and CNS disorders, expanding treatment options for previously untreatable genetic conditions.

ELIOS develops a technology that restores the normal flow of aqueous humor in glaucoma patients, effectively reducing intraocular pressure. This approach directly addresses the risk of vision loss associated with elevated eye pressure, providing a targeted solution for managing glaucoma.

Horizon Surgical Systems develops assistive surgical robotics platforms, such as Polaris™, specifically engineered for ophthalmic procedures like cataract surgery. This technology integrates real-time 3D imaging, machine learning, and microsurgical dexterity to enhance surgeon performance and standardize surgical outcomes. The platform aims to improve the consistency and accessibility of high-quality vision restoration procedures for a growing patient population.

Novai develops early detection and intervention methods for eye and brain diseases using proprietary DARC technology. This platform provides clinicians with faster data for appropriate treatment selection and supports pharmaceutical companies in ophthalmic drug development. The technology aims to prevent severe vision loss and disability through advanced diagnostic capabilities.

QURA develops ultra-miniature implantable devices that continuously monitor physiological pressure changes in real-time. These devices provide critical data for early detection of health issues, enhancing patient care and enabling timely medical interventions.

Retro provides a social application focused on connecting friends on a weekly basis. The platform facilitates ongoing, low-pressure social interaction among established peer groups. It offers a dedicated space for friends to maintain consistent, casual connection.

Re-Vana Therapeutics develops biodegradable ocular implants using patented photo-crosslinked technology for sustained intraocular release of biologics and small-molecule drugs over six months. This approach addresses the need for reduced frequency of drug administration in patients with sight-threatening diseases, enhancing treatment adherence and patient outcomes.

Stic operates a mobile out-of-home advertising network by equipping high-mileage drivers with ad placements. The platform allows brands and agencies to execute geo-targeted campaigns with real-time impression tracking and performance monitoring. This system converts daily commutes into measurable media inventory for targeted audience reach.

Trefoil Therapeutics is developing TTHX1114, an engineered Fibroblast Growth Factor (FGF1), for the treatment of corneal diseases affecting both the epithelial and endothelial layers of the cornea. The intracameral injection and topical formulations aim to improve visual recovery and reduce epithelial damage in patients with conditions such as Fuchs endothelial corneal dystrophy and other corneal injuries.

Valitor employs its proprietary Multivalent Polymer (MVP) platform to conjugate multiple copies of anti‑VEGF proteins onto a custom biopolymer scaffold, creating a long‑acting ocular biologic. The lead candidate, VLTR‑559, achieves six‑month therapeutic exposure after a single intravitreal injection while maintaining potency comparable to current short‑acting agents. The modular MVP system enables rapid development of additional ophthalmic and non‑ocular macromolecular therapeutics.